The Vaccine Company, a Delaware corporation formed in 2003, was founded to commercialize the PR1 vaccine developed at the M.D. Anderson Cancer Center at the University of Texas. The vaccine is currently in Phase I/II trials for relapsed refractory AML (acute myelogenous leukemia), CML (chronic myelogenous leukemia) failing current therapies and advanced myelodysplasia. The Vaccine Company has an exclusive worldwide license to the technology from the M.D. Anderson Cancer Center. The license includes exclusive rights to the PR1 vaccine and other potential peptide vaccines, which the company intends to advance to clinical trials. Regarding the current Phase I/II trials at present, the clinical response rate is 26% including hematological responses, cytogenetic remissions, and molecular remissions. The remissions are durable. There also seems to be a survival advantage in patients who had an immunological response, but no overt clinical response.

Click Here to contact us about the The Vaccine Company.

InvestBio structures institutional quality investment opportunities for the qualified individual investor. Our scientific advisors have access to valuable industry insights, allowing us to identify the most promising research and drugs. We structure an investment partnership for our clients and typically invest side-by-side, at the same price and timing, in targeted private equity investments. This approach allows our interests to be directly aligned with our investors. On Wall Street, these investment opportunities are often only accessible to institutional investors, however, we at InvestBio believe that these opportunities should also be available to the qualified individual investor. We make that happen. InvestBio is a wholly owned subsidiary of DPEC Partners.